» Articles » PMID: 28151796

Clinical and Prognostic Features of Patients With Esophageal Cancer and Multiple Primary Cancers: A Retrospective Single-institution Study

Overview
Journal Ann Surg
Specialty General Surgery
Date 2017 Feb 3
PMID 28151796
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the clinical and prognostic characteristics of patients with esophageal cancer and multiple primary cancers.

Summary Background Data: Patients with esophageal cancer frequently have multiple primary cancers, the presence of which may complicate physicians' decision-making because the clinical and prognostic features of such patients remain unknown.

Methods: This retrospective single-institution study included 538 consecutive patients who had undergone resection of esophageal cancer. The Cox proportional hazard model was used to compute the hazard ratio (HR) for mortality.

Results: At the time of surgery, 163 patients (30%) had multiple primary cancers (77, metachronous; 86, synchronous). Multiple primary cancers were significantly associated with alcohol use and tobacco smoking (Brinkman index). Patients with synchronous cancers had significantly shorter overall survival than those without multiple primary cancers (log-rank P = 0.032; univariate HR = 1.53, 95% confidence interval 1.02-2.17, P = 0.040; multivariate HR: 1.61; 95% confidence interval: 1.08-2.36; P = 0.020). Patients with metachronous cancers had similar prognoses to those without multiple primary cancers. The prognostic effect of synchronous cancers on overall survival was particularly prominent in patients with Stage I esophageal cancer (log-rank P = 0.0002).

Conclusions: Multiple primary cancers are associated with a history of tobacco and alcohol use, supporting the concept of field cancerization. Synchronous multiple primary cancers may be an independent predictor of poorer long-term survival in patients undergoing resection of esophageal cancers.

Citing Articles

Case report: Long-term survival in synchronous double primary malignancies of lung adenocarcinomas and esophageal squamous cell carcinoma treated with definitive chemoradiotherapy and SBRT combined with anti-PD-1.

Zeng R, Zhou X, Ou K, Chen W, Yang C, Wang T Front Immunol. 2025; 16:1548176.

PMID: 40028319 PMC: 11867956. DOI: 10.3389/fimmu.2025.1548176.


Advancements and challenges in esophageal carcinoma prognostic models: A comprehensive review and future directions.

Chen J, Xing Q World J Gastrointest Oncol. 2025; 17(2):101379.

PMID: 39958560 PMC: 11755996. DOI: 10.4251/wjgo.v17.i2.101379.


Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II-IVa esophageal cancer: a network meta-analysis.

Wang M, Dong W, Wu G, Zhang B, Lai T, Liu A Syst Rev. 2025; 14(1):26.

PMID: 39871293 PMC: 11773777. DOI: 10.1186/s13643-025-02765-8.


Revolutionizing ESCC prognosis: the efficiency of tumor-infiltrating immune cells (TIIC) signature score.

Wang H, Ma S, Yang Z, Niu R, Zhu H, Li S Discov Oncol. 2025; 16(1):65.

PMID: 39833504 PMC: 11747060. DOI: 10.1007/s12672-024-01709-3.


Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases.

Guo W, Zhou B, Dou L, Guo L, Li Y, Qin J Exp Mol Med. 2024; 57(1):59-71.

PMID: 39741182 PMC: 11799171. DOI: 10.1038/s12276-024-01369-x.